Aptevo Therapeutics (APVO) vs Onconetix (ONCO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Onconetix is the larger company by market cap ($3.4 million vs $3.3 million), about 1.1 times the size. On valuation, Onconetix trades at a lower trailing P/E (0.0x vs 0.0x for Aptevo Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | APVO | ONCO |
|---|---|---|
| Share price | $1.80 | $0.6543 |
| Market cap | $3.26M | $3.43M |
| 1-day change | -2.17% | +9.56% |
| P/E ratio (TTM) | 0.03 | 0.00 |
| EPS (TTM) | $66.96 | $310.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $31.14 | $207.00 |
| 52-week low | $1.37 | $0.58 |
| Distance from 52-week high | -94.22% | -99.68% |
| Analyst consensus | none | — |
| Avg. price target upside | +1316.67% | — |
| Average volume | 91.51K | 2.96M |
| Shares outstanding | 1.81M | 5.24M |
| Employees | 33 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Aptevo Therapeutics trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).
About Aptevo Therapeutics
APVO stock →Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
Healthcare · Biotechnology · 33 employees
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Healthcare · Biotechnology · 2 employees
APVO vs ONCO FAQ
Which is bigger, Aptevo Therapeutics or Onconetix?
Onconetix (ONCO) is larger, with a market capitalization of $3.43M compared with $3.26M for Aptevo Therapeutics (APVO).
Which has the lower P/E ratio, APVO or ONCO?
ONCO has the lower trailing P/E at 0.0, versus 0.0 for APVO. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Aptevo Therapeutics and Onconetix in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.